Cabozantinib is a multi-kinase inhibitor targeting MET, VEGFR-1/2/3, AXL, RET, ROS1, and others—interfering with tumor growth, angiogenesis, and metastatic progression.

CABOMETYX is indicated for:

Renal Cell Carcinoma (RCC)

• • As monotherapy for advanced RCC.

  • First-line treatment in combination with nivolumab.

Hepatocellular Carcinoma (HCC)

• • For patients previously treated with sorafenib.

Differentiated Thyroid Cancer (DTC)

• • For patients aged 12+ with locally advanced/metastatic DTC after VEGFR-targeted therapy and who are RAI-refractory or ineligible.

Neuroendocrine Tumors (NETs)

• • Pancreatic (pNET) and Extra-pancreatic (epNET), previously treated, unresectable, locally advanced, or metastatic.

  • Approved for adults and pediatric patients aged 12+.

Monotherapy (RCC, HCC, DTC, NET) - 60 mg once daily

Combination (with nivolumab for RCC) - CABOMETYX 40 mg daily + nivolumab 240 mg q2w or 480 mg q4w

Pediatric (<40 kg) - 40 mg once daily

Monotherapy:

• ≥20%: Diarrhea, fatigue, PPE, appetite loss, hypertension, nausea, vomiting.

With Nivolumab:

• Added risk of: Hepatotoxicity, stomatitis, rash, hypothyroidism, musculoskeletal pain, URTIs.

None

CABOMETYX has a broad array of potential serious side effects, including:

• Hemorrhage (discontinue if Grade 3 or 4)
• GI perforations and fistulas
• Thromboembolic events
• Hypertension/hypertensive crisis
• Diarrhea and Palmar-Plantar Erythrodysesthesia (PPE)
• Hepatotoxicity (especially with nivolumab)
• Adrenal insufficiency, thyroid dysfunction, hypocalcemia
• Osteonecrosis of the jaw, impaired wound healing
• Reversible Posterior Leukoencephalopathy Syndrome (RPLS)